「poc」の検索結果

Builds clear, executable, and auditable inclusion and exclusion criteria for biomedical and clinical research protocols. Always use this skill when a user needs to translate a target population into operational screening rules tied to chart fields, time windows, tests, procedures, prior therapies, exclusions, and reviewable edge cases. Focus on protocol-stage precision, ambiguity reduction, auditability, and screening reproducibility rather than generic study design advice.

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete phenotype-scoring bioinformatics research designs for any disease context and any user-defined phenotype, pathway, process, signature, or molecular program. Use when a study centers on gene-set or feature-set definition, intersection with DEGs or candidate features, phenotype scoring, feature selection, diagnostic or stratification assessment, immune or cellular-resolution interpretation, network analysis, and optional orthogonal validation. Covers five study patterns (signature discovery, phenotype scoring, feature selection, immune/cellular interpretation, multi-layer validation) and always outputs Lite / Standard / Advanced / Publication+ with a recommended primary plan, stepwise workflow, figure plan, validation hierarchy, minimal executable version, publication upgrade path, and strictly verified literature retrieval.

日本語の概要は準備中です。原文の説明を表示しています。

Designs a realistic, execution-aware biomedical study version under explicit constraints of samples, time, budget, data access, lab capacity, team skill, and validation resources. Always use this skill when the user has a real study idea, a candidate route, or a partially framed project but cannot assume ideal conditions. If critical feasibility inputs are missing, first clarify what resources are currently available, what resources may be obtainable, and what resources are realistically unavailable. Do not invent access, capabilities, collaborations, or validation resources. Focus first on feasibility-constrained study framing, route narrowing, dependency control, and minimum viable study design.

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete FAERS-style pharmacovigilance disproportionality research designs from a user-provided drug class, comparator strategy, adverse-event domain, and patient-group stratification. Always use this skill whenever a user wants to design, plan, or build a spontaneous-report safety signal study using FAERS or a similar pharmacovigilance database, especially when the article logic includes product selection, indication-group stratification, MedDRA-based adverse-event extraction, serious-case filtering, suspect-drug and concomitant-exclusion logic, reporting odds ratio analysis, comparator-drug benchmarking, cross-drug comparison, and cautious signal interpretation without causal overclaiming. Covers five study patterns (single-drug disproportionality workflow, multi-drug class comparison workflow, indication-stratified workflow, comparator-controlled signal screening workflow...

日本語の概要は準備中です。原文の説明を表示しています。

Designs primary, secondary, and exploratory endpoints for biomedical and clinical research protocols. Always use this skill when a user needs to translate study aims into operational endpoint definitions with event rules, assessment timing, composite logic, interpretability, and protocol-stage auditability. Focus on endpoint precision, feasibility, clinical meaning, ambiguity reduction, and implementation readiness rather than generic study design advice.

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete dual-disease shared-transcriptome biomarker and hub-gene research designs from a user-provided disease pair and shared-biology direction. Always use this skill whenever a user wants to design, plan, or build a non-oncology two-disease transcriptome study centered on per-disease differential expression, shared-signal intersection or concordance, PPI-based hub-gene prioritization, diagnostic evaluation across both diseases, immune infiltration context, pathway interpretation, and optional orthogonal validation. Covers five study patterns (shared-DEG-first workflow, hub-gene-first shared-biomarker workflow, hybrid shared-biomarker compression workflow, immune-context shared-biomarker workflow, orthogonal validation workflow) and always outputs four workload configs (Lite / Standard / Advanced / Publication+) with recommended primary plan, step-by-step workflow, figure plan, validation strategy, minimal executable version, publication upgrade path...

日本語の概要は準備中です。原文の説明を表示しています。

Design evidence-discovery and validation workflows for drug repurposing studies by integrating disease mechanisms, drug-target logic, expression reversal, real-world evidence, and validation routes into a closed-loop study blueprint.

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete cross-disease shared-biomarker bioinformatics research designs from a user-provided disease pair and validation direction. Always use this skill whenever a user wants to design, plan, or build a multi-dataset study linking two related diseases through shared DEGs, enrichment, PPI hub genes, public validation, regulatory-network analysis, immune infiltration, drug-gene interaction screening, and optional qRT-PCR or cell-line validation. Covers five study patterns (shared-DEG discovery, hub-gene prioritization, regulatory-network interpretation, immune/drug follow-up, bioinformatics-plus-validation) and always outputs four workload configs (Lite / Standard / Advanced / Publication+) with recommended primary plan, step-by-step workflow, figure plan, validation strategy, minimal executable version, publication upgrade path, and a strictly verified reference literature retrieval layer with real references only.

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete conventional oncology bulk-transcriptome biomarker and hub-gene research designs from a user-provided cancer type and study direction. Always use this skill whenever a user wants to design, plan, or build a tumor bioinformatics study centered on differential expression, prognostic filtering or risk modeling, PPI-based hub-gene prioritization, diagnostic/prognostic evaluation, clinical association, immune infiltration context, methylation context, and optional tissue or cell validation. Covers five study patterns (signature-first prognostic workflow, hub-gene-first biomarker workflow, hybrid signature-to-hub workflow, immune-context biomarker workflow, translational validation workflow) and always outputs four workload configs (Lite / Standard / Advanced / Publication+) with recommended primary plan, step-by-step workflow, figure plan, validation strategy, minimal executable version, publication upgrade path...

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete conventional non-oncology bioinformatics research designs from a user-provided disease context, process-related gene family or biological theme, and validation direction. Use when a study centers on multi-dataset bulk transcriptome integration, DEG analysis, process-gene intersection, enrichment analysis, GSEA, PPI hub-gene prioritization, TF/miRNA regulatory networks, ROC-based biomarker evaluation, and immune infiltration analysis. Covers five study patterns (process-DEG discovery, enrichment/GSEA interpretation, hub-gene prioritization, regulatory-network and immune interpretation, multi-layer public validation) and always outputs Lite / Standard / Advanced / Publication+ with a recommended primary plan, stepwise workflow, figure plan, validation hierarchy, minimal executable version, publication upgrade path, and strictly verified literature retrieval.

日本語の概要は準備中です。原文の説明を表示しています。

Plans confounder control, variable adjustment logic, and bias mitigation strategies at the protocol stage for clinical, epidemiologic, translational, observational, and biomarker studies. Always use this skill when a user needs to identify major confounders, decide which variables should or should not be adjusted for, compare matching/stratification/weighting approaches, anticipate selection or measurement bias, or pressure-test a study design before execution. Focus on bias sensing, causal structure awareness, variable-role classification, and critical design review rather than generic statistical advice.

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete comparative network-toxicology research designs from a user-provided exposure pair, shared toxic phenotype, and validation direction. Use when a study centers on two related exposures under one outcome and needs target collection, shared-vs-specific target decomposition, enrichment, PPI hub prioritization, docking, optional transcriptomic cross-checks, and conservative mechanistic synthesis. Covers five study patterns and always outputs Lite / Standard / Advanced / Publication+ with a recommended primary plan, stepwise workflow, figure plan, validation hierarchy, minimal executable version, publication upgrade path, and strictly verified literature retrieval.

日本語の概要は準備中です。原文の説明を表示しています。

Designs retrospective or prospective clinical cohort study protocols for biomedical and clinical research. Always use this skill when the user needs a cohort-based study plan rather than a general study idea, evidence summary, or mechanistic experiment design. Focus on cohort appropriateness, enrollment logic, baseline time-zero definition, follow-up structure, endpoint definition, variable collection, confounding control, and a coherent primary statistical analysis line. Do not invent data availability, follow-up completeness, outcome ascertainment quality, sample size adequacy, or causal interpretability.

日本語の概要は準備中です。原文の説明を表示しています。

Design a structured case-control study framework with explicit source population logic, control selection rules, matching decisions, exposure measurement planning, and bias-control checkpoints.

日本語の概要は準備中です。原文の説明を表示しています。

Refines long medical academic texts into SCI-style unstructured Chinese and English abstracts; use when you need to condense drafts/reports/summaries into bilingual abstracts and generate Summary_Report.md.

日本語の概要は準備中です。原文の説明を表示しています。

Generate interactive anatomy quizzes for medical education with multiple.

日本語の概要は準備中です。原文の説明を表示しています。

Use when performing PCA principal component dimensionality reduction on tabular numeric data. Supports command-line parameter input, automatic numeric feature selection, parameter validation, result directory creation, and CSV or TXT format result export.

日本語の概要は準備中です。原文の説明を表示しています。

Academic paper reading and research development system for biomedical researchers. Finds papers via Semantic Scholar, reads with structured notes, tracks discussion insights, and synthesizes literature into a Research Foundation Document (RFD) for downstream protocol design skills. 8 commands: /setup /feed /read /discuss /recap /update /sync /propose

日本語の概要は準備中です。原文の説明を表示しています。

Use when you need a standardized R CLI workflow to build a protein-protein interaction network from a local gene list and an offline STRING cache, export node and edge tables, and render a reproducible PDF network plot. NOT for online API fetching, arbitrary graph databases, multi-omics integration, or non-STRING interaction sources.

日本語の概要は準備中です。原文の説明を表示しています。

Explains why studies on the same biomedical topic reach different or opposing conclusions by auditing differences in population, endpoint definition, sample source, assay or platform, study design, statistical model, adjustment strategy, validation chain, and bias control. It separates true contradiction from apparent contradiction caused by framing or methods. Never fabricate references, PMIDs, DOIs, trial identifiers, dataset details, platform details, study features, or conflict explanations that are not supported by the input.

日本語の概要は準備中です。原文の説明を表示しています。

Systematically maps mechanism evidence for a disease from molecules to pathways, cell types, tissues, biological consequences, and clinical phenotypes. Always use this skill when a user needs a layered mechanism evidence chain rather than a flat summary or immediate gap analysis. Formal literature citations must be real and verifiable.

日本語の概要は準備中です。原文の説明を表示しています。

Organizes the evidence and competitive landscape around a drug, target, or pathway by separating disease relevance, tractability, preclinical evidence, clinical evidence, modality fit, and crowding. Always map what is biologically supported, what is druggable, what has actually advanced, and what remains strategically open. Never confuse target relevance with druggability, preclinical activity with clinical promise, or narrative excitement with validated development maturity. Never fabricate references, trial status, approval status, company activity, or asset metadata.

日本語の概要は準備中です。原文の説明を表示しています。

Ranks papers by evidence family, methodological quality tier, validation depth, and claim discipline; assigns anchor, context-setting, mechanistic support, or caution citation roles; prevents prestige-based or design-label-based ranking errors.

日本語の概要は準備中です。原文の説明を表示しています。

Reads a paper figure by figure before re-integrating the full narrative, so the user can identify the core findings quickly and check whether each visual actually supports the authors' main claims. Always separate figure content, figure-linked claim, evidentiary strength, and unsupported interpretation. Never fabricate references, PMIDs, DOIs, figure content, panel labels, result values, or study details that were not actually provided.

日本語の概要は準備中です。原文の説明を表示しています。